LOS ANGELES
HemaCare Corporation,(OTCBB:HEMA) a leader in cell and tissue collection, processing and cell therapy solutions, today announced that it will be attending the ISCT meeting May 25-28th at the Suntec Convention and Exhibit Centre in Singapore, to support the society’s annual gathering of clinicians, regulators, researchers and other industry partners, whose objective is to translate cellular therapy into safe and effective treatments to improve patient’s lives. This is the first time the ISCT is conducting its annual meeting in Asia, and consequently, there will be added focus on current and future developments of cell therapy delivery and commercialization in Asia, a region where HemaCare has recently expanded through distribution partners. HemaCare will also present a poster session to highlight its core competencies for supplying highly pure and viable human hematopoietic stem cells and mature primary cells in global demand by these investigators.
HemaCare is the recognized apheresis leader in supporting autologous and allogeneic cell therapy. What sets HemaCare apart from other providers is heritage as a transfusable collection center with over 38 years of experience operating an FDA registered, cGMP/cGTP compliant donor center. HemaCare staff has performed over 250,000 apheresis collections and have been performing patient leukapheresis collections for clinical trials and commercialized immunocellular therapy for over a decade. HemaCare manages hundreds of reliable and recallable donors, who can meet various criteria for selection to be used for allogeneic cell therapy starting material globally.
“We are supporting ISCT as part of our dedication to help developers of innovative cell therapies make critical advances that offer medical solutions for patients with chronic illnesses. HemaCare’s portfolio of human primary hematopoietic cells is a necessary component for these researchers to develop and implement these innovative treatments and cures for diseases where the body’s own immune system can be programmed to fight the disease,” said Pete van der Wal, HemaCare’s Chief Executive Officer. “We understand the critical need researchers have for our products and specialized capabilities and will continue to support these important meetings as we dedicate our business to aid in the pursuit of these treatments.”
View our product story at www.hemacare.com or visit us in Singapore at ISCT at booth C18.
About HemaCare
Since 1978, HemaCare Bioresearch Products & Services has been the trusted research partner of choice from concept to commercialization. Built on a 38-year history in apheresis collection, HemaCare is a leader in Cell and Tissue Collection, providing the high-quality biological material needed to ensure quality research outcomes that meet the unique needs of the scientific community. HemaCare’s expertise extends to serving biopharmaceutical firms with autologous and allogeneic collections used for Cell Therapy research, process development, and clinical trials. For more information please visit www.hemacare.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160523005030/en/
CONTACT
HemaCare Corporation
Chris Brotski
818-251-5335
cbrotski@hemacare.com
